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Abstract 
Total of 6840 clinical samples were collected from King Fahd 
Hospital at Medina, Kingdom of Saudi Arabia (KSA). Clinical samples were 
screened for Proteus spp. It is found that Proteus spp isolates representing 
about 3% of all positive samples isolated from different clinical sources. 
Males were found to be more vulnerable than females in acquiring Proteus 
infections. Results showed that the greatest number of Proteus spp. isolates 
from clinical specimens were isolated from wound and sputum swabs 
specimens representing about 88% of all clinical specimens.  
Thirteen different antibiotics representing different families of antibiotics 
were tested on Proteus spp. specimens for studying its antimicrobial 
sensitivity pattern. Results of antimicrobial sensitivity tests revealed that 
imipenem (IMP) antibiotic was the most effective antibiotic against Proteus 
spp. with 91% of antimicrobial sensitivity. Imipenem (Imp) was followed by 
amikacin (AK) with 61% of antimicrobial sensitivity.  
Results are recommending prescribing of imipenem (IMP) antibiotic in the 
treatment of Proteus spp infections. It is recommended also to prescribe 
amikacin (AK) in the case of sensitivity to imipenem (IMP). In acute cases, 
Proteus infections could require use of combined antimicrobial therapy 
(imipenem- amikacin). Results also demonstrated that percentage of Proteus 
spp. infections was highest during summer season representing about 40% of 
infections all year along. Summer season was followed by winter season 
with about 32% of infections. 
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Introduction 
Proteus is a genus of Gram-negative bacteria belonging to the family 
of Enterobactericeae. Proteus species are distinguishable from most other 
genera by their ability to swarm across an agar surface (Jacobsen et al., 
2008). Proteus is widespread in the environment and makes up part of the 
normal flora of the human gastrointestinal tract. Proteus ranks third as the 
cause of hospital-acquired infections (Stamm, 1999). Three species: P. 
vulgaris, P. mirabilis, and P. penneri  are opportunistic human pathogens 
(Guentzel, 1996). 
Proteus species are the major cause of diseases acquired outside the 
hospital, where many of these diseases eventually require hospitalization (De 
Champs et al, 2000). P. mirabilis causes 90% of Proteus infections. Proteus 
species, particularly P. Mirabilis, is believed to be the most common cause 
of infection-related kidney stone, one of the most serious complications of 
unresolved or recurrent bacteruria (Coker et al., 2000). 
P. mirabilis has been implicated in meningitis, empyema, 
osteomyelitis and gastroenteritis. Also, it frequently causes nosocomial 
infections of the urinary tract (46%), surgical wounds (24%) and lower 
respiratory tract (30%). Less frequently, proteus species cause bacteraemia 
(17%), most often in elderly patients (Mansy, 2001).  
The phenomenal evolution and increase of multidrug-resistance of 
many bacterial pathogens is increasing and representing a growing public 
health problem in the world. 
Evolution and spread of a multidrug-resistant Proteus mirabilis clone 
with chromosomal AmpC-type beta-lactamase was reported in Europe 
(Luzzaro et al., 2009; D'Andrea et al., 2011)  
Multidrug-resistance of Proteus spp. calls for regular review of 
antimicrobial sensitivity pattern among clinically isolated Proteus spp. in 
order to be able to decide which antibiotic to be prescribed. 
Materials and methods 
Specimens’ collection 
Different clinical samples such as sputum, wound swab, 
cerebrospinal fluid (CSF), tracheal aspirate (Tr. asp.), throat aspirate (Th. 
asp.), catheter Tip, pus, abdominal abscess (Abd. ab.), ear swab, bed sores, 
peritoneal wound swab (Peri. w.s.), pleural fluid (Pler. fluid), were 
collected from 6840 patients suspected of bacterial infection at King Fahd 
Hospital at Medina, Kingdom of Saudi Arabia (KSA). Clinical samples 
were cultured to isolate the organisms. Demographic data such as sex of the 
patients was recorded prior to sample collection. 
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Cultivation and Identification 
The clinical samples collected were aseptically inoculated on plates 
of Blood agar, Chocolate agar Cystine-Lactose-Electrolyte-Deficient 
(CLED) agar and MacConkey agar (Oxoid Cambridge, UK) and incubated at 
37ºC for 24 h. The morphological characteristics of the colonies including 
size, shape, colour, pigmentation and haemolytic nature were recorded. 
Suspected Proteus colonies were isolated and identified through biochemical 
tests according to Barrow and Felthan:[9] based on whether they were 
positive for nitrate reduction; H2S gas production; methyl-red and urease 
reactions; and negative for lactose fermentation.  
Antimicrobial susceptibility test 
Susceptibility to antimicrobial agents was determined by using the 
disk diffusion method (Oqunshe, 2006). The following antimicrobial agents 
(obtained from BDH London, UK) were used: ampicillin (AP), augmentin 
(AUG), gentamycin (GM), cefoxitin (FOX), cephalothin (KF), 
cotrimoxazole (TS), amikacin (AK), ceftazidime (CAZ), aztreonam (AZT), 
piperacilline (PRL), imipenem (IMP), ciprofloxacin (CIP), cefpiramide 
(CPM).  
The inocula were prepared by growing the various Proteus species on 
separate agar plates and colonies from the plate were transferred with 
inoculating loop into 3 ml of normal saline in a test tube. The density of 
these suspensions was adjusted to 0.5 McFarland standards. The surface of 
Muller-Hinton agar (Oxoid Cambridge, UK) plate was evenly inoculated 
with the organisms using a sterile swab. The swab was dipped into the 
suspension and pressed against the side of the test tube to remove excess 
fluid. The wet swab was then used to inoculate the Muller-Hinton agar by 
evenly streaking across the surface. By means of Disc Dispenser (Oxoid 
Cambridge, UK), the antibiotic discs were applied to the surface of the 
inoculated agar and the plates were incubated overnight at 37ºC. The 
diameter of zone of growth-inhibition observed was measured and compared 
to the chart provided by National Committee for Clinical Laboratory 
Standards (NCCLS). 
Results and discussion 
Total 6840 clinical samples were collected in the period from 
22/6/2011 to 22/8/2012 (14 months) from King Fahd Hospital at Medina, 
Kingdom of Saudi Arabia (KSA).  Clinical samples were screened for 
Proteus spp. It is found that 193 isolates were identified as Proteus spp. 
representing about 3% of all positive samples isolated from sputum, wound 
swab, cerebrospinal fluid (CSF), tracheal aspirate (Tr. asp.), throat aspirate 
(Th. asp.), catheter Tip, pus, abdominal abscess (Abd. ab.), ear swab, bed 
sores, peritoneal wound swab (Peri. w.s.), pleural fluid (Pler. fluid); (Figure 
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1). Results showed completely absence of isolates from many sources such 
as urine, blood, semen, ascetic fluid, nasal swabs, axilla, perineum, etc…  
The calculated percentage of Proteus spp. in relation to other 
clinically isolates were not far away from other studies reported similar 
results. O’Hara et al, (2000) reported that P. mirabilis accounts for 
approximately 3% of nosocomial infections in the United States and is 
commonly isolated in clinical microbiology laboratories, where it is 
probably responsible for 6000,000 patients each year. In the same trend 
Sekowska et al. (2004) reported that P. mirabilis strains were isolated from 
4.3% of all positive samples isolated from urine, wounds and ulcers. Also, 
Feglo et al. (2010) reported a prevalence rate of 8.4 % of Proteus species 
collected from clinical samples. 
 
Figure (1): Percentage of Proteus spp. isolates to other clinical isolates 
 
It is found that one hundred forty four samples representing 75% of 
positive Proteus isolates were taken from male patients, while forty nine 
samples representing 25% of positive Proteus isolates were taken from 
female patients; (Figure 2). Males were found to be more vulnerable than 
females in acquiring Proteus infections. 
We have no adequate studies concerned with gender distribution of 
Proteus infections. This gender distribution was different from that reported 
by Feglo et al. (2010), who reported that 43 % of Proteus species collected 
from clinical samples were taken from male patients while  57 % from 
females. 
Our results with male patient predominance are most likely due to the 
fact that male exposure is greater as they are representing the majority of 
workforce in Kingdom of Saudi Arabia, so they are exposed more to 
acquiring infectious diseases, to road traffic accidents and more to metallic 
fixation of the bone fractures and other operations.   
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Figure 2: Percentage of males and females positive Proteus spp. Isolates 
 
Table (1) showing numbers of males and females specimens 
isolated from different sources. Seventy four isolates were isolated from 
sputum specimens (sixty isolates from males and fourteen isolates from 
females); seventy six isolates were isolated from wound swabs specimens 
(fifty two isolates from males and twenty four isolates from females); three 
isolates were isolated from cerebrospinal fluid (CSF) specimens (three 
isolates were from males); eleven isolates were isolated from tracheal 
aspirate (Tr. asp.) specimens (nine isolates from males and two isolates 
from females); twenty isolates were isolated from catheter tip specimens 
(thirteen isolates from males and seven isolates from females); only one 
isolate was isolated from throat aspirate (Th. asp.), pus, abdominal abscess 
(Abd. ab.), and ear swabs specimens (isolated from men); two isolates were 
isolated from bed sores specimens (one isolate from each gender); two 
isolates were isolated from peritoneal wound swab (Peri. w.s.) specimens 
(isolated from men); one isolate was isolated from pleural fluid (Pler. 
Fluid) specimens (isolated from a woman). 
Table 1: Numbers of males and females specimens isolated from different sources: 
Sex Source of specimens 
Sputu
m 
Wou
nd 
swab 
CS
F Tr. 
asp. 
Th
. 
as
p. 
Cathet
er Tip 
Pus Ab
d. 
ab. 
Ear 
swa
b 
Bed 
sor
es 
Peri
. 
w.s. 
Pler
. 
flui
d 
Males 60 52 3 9 1 13 1 1 1 1 2 0 
Femal
es 14 24 0 2 
0 7 0 0 0 1 0 1 
Total 74 76 3 11 
1 20 1 1 1 2 2 1 
CSF: Cerebrospinal fluid, Tr. asp.: Tracheal aspirate, Th. asp.: Throat aspirate, Abd. ab.: 
Abdominal abscess, Peri. w.s.: Peritoneal wound swab, Pler. fluid: Pleural fluid 
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The calculated percentages of positive Proteus spp. specimens 
isolated from different clinical samples are shown in Figure (3). It is found 
that positive Proteus spp. specimens isolated from sputum, wound swabs, 
cerebrospinal fluid (CSF),  tracheal aspirate (Tr. asp.), throat aspirate (Th. 
asp.), catheter tip, , pus,  abdominal abscess (Abd. ab.), ear swabs, bed sores, 
peritoneal wound swab (Peri. w.s.), and pleural fluid (Pler. Fluid) specimens 
were representing 38.34, 49.74, 1.55, 5.67, 0.52, 10.36, 0.52, 0.52, 0.52, 
1.36, 1.36, and 0.52%, respectively. 
Results showed that the greatest number of Proteus spp. isolates from 
clinical specimens were isolated from wound and sputum swabs specimens 
representing about 88% of all clinical specimens, while the percentage of  
Proteus spp. isolates from throat aspirate (Th. asp.), pus,  abdominal abscess 
(Abd. ab.), ear swabs, and pleural fluid (Pler. Fluid) specimens were the least 
representing no more than 0.52%.  
Being wound isolates were the highest (49.47%) are in the same trend 
with many results. This result agrees with similar studies conducted in 
England, Wales and Northern Ireland. (Chow et al., 1979; Jones et al., 2003). 
Wounds recorded the highest percentage of Proteus isolates (64.5 %) and 
this confirmed the findings of Newman et al. (2006) in Ghana; Yah et al. 
(2001) in Nigeria; and Feglo et al. (2010) in Ghana. Proteus seems to be a 
common cause of wound infections in West Africa , in contrast with those 
from Europe and Asia (Reslinski et al., 2005; Orett, 1999) which showed 
Proteus species to be more commonly encountered in urine than in other 
clinical specimens. 
 
Figure 3: Percentage of positive Proteus spp. specimens isolated from different clinical 
samples 
The calculated percentages of males and females specimens isolated 
from different sources are shown in Table (2) and Figure (4). Results 
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showed that about 80% of positive Proteus spp. isolates from sputum and 
tracheal aspirate (Tr. asp.) were collected from males, while about 65-70% of 
isolates from wound swabs and catheter tips were isolated from males. 
Percentages of other sources of specimens are not indicative for comparing 
males to females percentage seen to the low number of specimens. In 
conclusion results showed that males were found to be more vulnerable than 
females in acquiring Proteus infections from all types of considered clinical 
specimens. male patient predominance is elucidated previously on the base 
of the fact that male exposure to infections is greater.  
Table 2: Percentage of males and females specimens isolated from different sources: 
Sex 
(%) 
Source of specimens 
Sputu
m 
Wou
nd 
swab 
CS
F 
Tr. 
asp. 
Th
. 
as
p. 
Cathe
ter 
Tip 
Pu
s 
Ab
d. 
ab. 
Ear 
swa
b 
Be
d 
sor
es 
Per
i. 
w.s
. 
Ple
r. 
flui
d 
Males 81.08 68.42 
10
0 
81.8
2 
10
0 65 
10
0 
10
0 100 50 
10
0 0 
Female
s 18.92 
31.5
8 0 
18.1
8 0 35 0 0 0 50 0 100 
CSF: Cerebrospinal fluid, Tr. asp.: Tracheal aspirate, Th. asp.: Throat aspirate, Abd. ab.: 
Abdominal abscess, Peri. w.s.: Peritoneal wound swab, Pler. fluid: Pleural fluid 
 
 
Figure 4: Percentage of males and females specimens isolated from different sources 
 
Thirteen different antibiotics (ampicillin (AP), augmentin (AUG), 
gentamycin (GM), cefoxitin (FOX), cephalothin (KF), cotrimoxazole (TS), 
amikacin (AK), ceftazidime (CAZ), aztreonam (AZT), piperacilline (PRL), 
imipenem (IMP), ciprofloxacin (CIP), cefpiramide (CPM)) representing 
different families of antibiotics were tested on Proteus spp. specimens for 
studying its antimicrobial sensitivity pattern. Results of antimicrobial 
sensitivity tests (Table 3, 4 and Figure 5) revealed that imipenem (IMP) 
antibiotic (Figure 6) was the most effective antibiotic against Proteus spp. 
with percentage (%) of antimicrobial sensitivity of 91% of Proteus spp. 
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Imipenem (Imp) was followed by amikacin (AK) (Figure 7) with percentage 
(%) of antimicrobial sensitivity of 61% of Proteus spp. 
Imipenem (Imp) and amikacin (AK) were followed by cefoxitin 
(FOX), aztreonam (AZT), and piperacilline (PRL) with percentage (%) of 
antimicrobial sensitivity of 48.2, 47.7, and 44.1, respectively. The rest of the 
tried antibiotics had less than 40 % of antimicrobial sensitivity pattern. 
Results also showed that resistance of Proteus spp. was evident to the 
following antibiotics cotrimoxazole (TS), cefpiramide (CPM), ampicillin 
(AP), cephalothin (KF) with percentage (%) of antimicrobial resistance 
reaching higher than 80% Proteus spp. Four antibiotics (augmentin, 
amikacin, piperacilline, imipenem) yielded intermediate reactions ranging 
from 0.5 to 3.1%. 
Results are recommending prescribing of imipenem (IMP) antibiotic 
in the treatment of Proteus spp. because it is the most effective antibiotic 
against Proteus spp in vitro. Although Proteus spp. are less sensitive to 
amikacin (AK) antibiotic, it is recommended to be prescribed in the case of 
sensitivity to imipenem (IMP). In acute cases Proteus infections could 
require use of synergic combined antimicrobial therapy (imipenem- 
amikacin).  
Attention should be paid to the increasing resistance of Proteus spp. 
to many antibiotics especially augmentin, amikacin, piperacilline, and 
imipenem. So, those antibiotics should not be prescribed to treat Proteus 
infection cases, as a multidrug resistance would be produced. 
The antimicrobial susceptibility testing carried out by El-Tahawy 
(2000) showed that imipenem was the most effective against gram-negative 
organisms. 
The study carried out by Makled and Alghamdi (2006) showed that 
aminoglycosides commonly used in treatment of infections caused by Pr. 
mirabilis isolates are still effective. 
Resistance of 77-85% of Proteus spp. against ampicillin, co-
trimoxazole, tetracycline, and chloramphenicol was reported by Feglo et al. 
(2010). Similar results were reported by Newman et al. (2006). 
 The high antibiotic resistance of Proteus spp. may be an indication of 
the resistance levels among the enterobacteriaceae and perhaps salmonellae 
since indiscriminate ingestion of antibiotics provides selective pressure, 
leading to a higher prevalence of resistant bacteria (Barrow and Felthan, 
2003). Not only are these species potential causes of infections but also 
potential reservoirs of resistance genes that could be transferred to other 
bacterial pathogens. The high levels of β-lactamase production and multi-
drug resistance of the isolates are indications of an increase in the resistance 
menace reported by many studies (Feglo et al., 2010). 
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Results of Fass et al. (1995) reported decreasing susceptibility of P. 
stuartii to ciprofloxacin from 100 to 46% over a 6-year period in their 
institution; are in the same trend with our results reporting 33% susceptibility 
of Proteus spp. isolates. 
 Swenson et al, (1999) showed that virtually all Proteus vulgaris and 
Proteus penneri strains are capable of producing inducible b-lactamases that 
will hydrolyze primary and extended-spectrum penicillins and 
cephalosporins (Swenson et al., 1999). For these reasons, the susceptibility 
of Proteus isolates needs to be monitored. 
The different Proteus species differs in their susceptibility pattern to 
different antibiotics.  For example, the indole-negative P. mirabilis strains 
are generally more susceptible to antimicrobials than are P. vulgaris, P. 
penneri, and P. hauseri. P. mirabilis has intrinsic resistance to nitrofurantoin 
and tetracycline but is generally susceptible to the amino- and ureido-
penicillins (ampicillin, amoxicillin, and piperacillin), cephalosporins 
(cefazolin, cefoxitin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, 
ceftizoxime, and cefepime), aminoglycosides (amikacin, gentamicin, and 
tobramycin), imipenem, ciprofloxacin, and trimethoprim-sulfamethoxazole 
(Fuchs et al., 1996; Ronald, 1994; Thornsberry and Yee, 1996; Yao and 
Moellering, 1999). However, high levels of ciprofloxacin resistance have 
been reported for P. mirabilis in hospitals where use of this agent is 
unrestricted (Thomson et al., 1994). In 1979, Chow et al. reported an 
outbreak of P. mirabilis that was resistant to ampicillin, cephalothin, 
tetracycline, chloramphenicol, carbenicillin, colistin, trimethoprim-
sulfamethoxazole, streptomycin, and the aminoglycosides (Chow et al., 
1979). An outbreak of P. mirabilis that was resistant to both gentamicin and 
the antiseptic chlorhexidine, as well as seven other antimicrobial agents, was 
reported as the cause of urinary tract infections in 90 patients in England in 
1987 (Dance et al., 1997). The source of the outbreak was linked to the 
introduction of a catheter care policy involving chlorhexidine. In an unusual 
outbreak in a hospital nursery, the strain of P. mirabilis that was responsible 
for bacteremias and meningitis in newborns was tetracycline susceptible. 
This very unusual antimicrobial pattern was used as a marker to trace the 
epidemiology (Burke et al., 1971). P. penneri is generally more resistant to 
penicillin than is P.vulgaris, and its susceptibility pattern more closely 
reflects that of M. morganii than that of P. vulgaris. These Proteeae are 
generally susceptible to cefoxitin, broad-spectrum cephalosporins 
(cefotaxime, ceftriaxone, ceftizoxime, and ceftazidime), cefepime, 
aztreonam, aminoglycosides, ciprofloxacin, tazobactam, and imipenem 
(Fuchs et al., 1996; Yao and Moellering, 1999) and may be resistant to 
cefazolin, cefprozil, cefuroxime, cefamandol, cefdinir, cefoperazone, 
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loracarbef, ampicillin, and the ureidopenicillins (Biedenbach and Jones, 
1994).  
Table 3: Antimicrobial sensitivity pattern of Proteus specimens to different antibiotics. 
Antibiotic Abbreviation Sensitive  Resistant  Intermediate  
Ampicillin AP 27 166 0 
Augmentin  AUG  64 128 1 
Gentamycin  GM  71 120 2 
Cefoxitin  FOX  93 100 0 
Cephalothin  KF  33 160 0 
Cotrimoxazole  TS  18 175 0 
Amikacin  AK  118 74 1 
Ceftazidime  CAZ  73 120 0 
Aztreonam  AZT  92 101 0 
Piperacilline  PRL  85 107 1 
Imipenem  IMP  175 12 6 
Ciprofloxacin  CIP  64 129 0 
Cefpiramide CPM 22 171 0 
 
Decreasing susceptibility of Proteus group and the potential for 
emerging resistance illustrated in this group needs for routine susceptibility 
tests (Fass et al., 1995). This study is therefore a step towards the generation 
of national data on the prevalence of antimicrobial resistance patterns of 
Proteus spp. 
Table 4: Percentage (%) of antimicrobial sensitivity pattern of Proteus specimens to 
different antibiotics. 
Antibiotic Abbreviation Sensitive 
(%) 
Resistant 
(%) 
Intermediate 
(%) 
Ampicillin AP 14 86 0 
Augmentin  AUG  33.2 66.3 0.5 
Gentamycin  GM  36.8 62.2 1 
Cefoxitin  FOX  48.2 51.8 0 
Cephalothin  KF  17.1 82.9 0 
Cotrimoxazole  TS  9.3 90.7 0 
Amikacin  AK  61.1 38.4 0.5 
Ceftazidime  CAZ  37.8 62.2 0 
Aztreonam  AZT  47.7 52.3 0 
Piperacilline  PRL  44.1 55.4 0.5 
Imipenem  IMP  90.7 6.2 3.1 
Ciprofloxacin  CIP  33.2 66.8 0 
Cefpiramide CPM 11.4 88.6 0 
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Figure 5: Percentage (%) of antimicrobial sensitivity pattern of Proteus specimens to 
different antibiotics 
 
 
 
Figure 6: Chemical structure of imipenem antibiotic 
(Chemical formula: C12H17N3O4S, Drugbank ID: DB01598) 
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Figure 7: Chemical structure of amikacin antibiotic 
(Chemical formula: C22H43N5O13, Drugbank ID: DB00479) 
 
Results (Table 5 and Figure 8 ) demonstrated that percentage of 
Proteus spp. infections was highest during summer season representing 
about 40% of infections all year along. Summer season was followed by 
winter season with about 32% of infections, and autumn season (which 
coincided with the season of pilgrimage) with about 22% of infections. 
While spring season has the least recorded percentage of Proteus infections 
with only 6% of infections.   
It is known long time ago that bacterial infections peak during 
summer season. Winter season also a candidate season for bacterial 
infections especially those concerned with respiratory system. Many studies 
reported incidence of seasons on increasing numbers of bacterial infections 
(O'Hara et al, 2000; Smith and Hogan, 2008; Bryan, 2011). 
It was clear that autumn season coinciding with the season of 
pilgrimage characterizing by the large number of delegations of pilgrims to 
Medina did not reported to be one of the highest seasons with infections 
(summer and winter) which could be attributed to success of control 
infections strategies taken by the health authorities which give special 
attention to fighting bacterial infections during pilgrims season to avoid 
epidemics. 
 
Table 5: Percentage (%) of Proteus infections pattern during different seasons: 
Season Percentage (%) of 
Proteus infections 
Summer  (22 June -22 September) 40 
Autumn  (23 September -21 December): Pilgrimage season 22 
Winter    (22 December -30 Mars) 32 
Spring     (21 Mars-21 June) 6 
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Figure 8: Percentage (%) of Proteus infections pattern during different seasons 
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